379 related articles for article (PubMed ID: 22077267)
1. Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: French healthcare payer perspective.
Luporsi E; Mahi L; Morre C; Wernli J; de Pouvourville G; Bugat R
J Med Econ; 2012; 15(2):225-32. PubMed ID: 22077267
[TBL] [Abstract][Full Text] [Related]
2. Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France.
Bourguignon S; Faller M; Champs FO; Moutier H; Levesque K; Caranhac G; Cohen-Solal A
ESC Heart Fail; 2019 Jun; 6(3):559-569. PubMed ID: 31021531
[TBL] [Abstract][Full Text] [Related]
3. Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy.
Rognoni C; Ortalda V; Biasi C; Gambaro G
Adv Ther; 2019 Nov; 36(11):3253-3264. PubMed ID: 31489572
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of implementing ESC guidelines for treatment of iron deficiency in heart failure in the Nordic countries.
Hofmarcher T; Cabrales Alin D; Linde C
Scand Cardiovasc J; 2018 Dec; 52(6):348-355. PubMed ID: 30457358
[TBL] [Abstract][Full Text] [Related]
5. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
[TBL] [Abstract][Full Text] [Related]
6. The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective.
Bager P; Dahlerup JF
J Crohns Colitis; 2010 Oct; 4(4):427-30. PubMed ID: 21122539
[TBL] [Abstract][Full Text] [Related]
7. [Economic impact of ferric carboxymaltose in haemodialysis patients].
Aiello A; Berto P; Conti P; Panichi V; Rosati A
G Ital Nefrol; 2020 Aug; 37(Suppl 75):. PubMed ID: 32749086
[TBL] [Abstract][Full Text] [Related]
8. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
Toblli JE; Di Gennaro F
PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
[TBL] [Abstract][Full Text] [Related]
9. Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia.
Szucs TD; Blank PR; Schwenkglenks M; Aapro M
Oncology; 2011; 81(1):45-9. PubMed ID: 21921645
[TBL] [Abstract][Full Text] [Related]
10. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
Pollock RF; Muduma G
Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
[TBL] [Abstract][Full Text] [Related]
11. Management of anemia in advanced breast and lung cancer patients in daily practice: results of a French survey.
Ray-Coquard I; Morère JF; Scotté F; Cals L; Antoine EC
Adv Ther; 2012 Feb; 29(2):124-33. PubMed ID: 22314432
[TBL] [Abstract][Full Text] [Related]
12. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom.
Pollock RF; Muduma G
J Med Econ; 2020 Jul; 23(7):751-759. PubMed ID: 32208038
[No Abstract] [Full Text] [Related]
13. Financial impact of intravenous iron treatments on the management of anaemia inpatients: a 1 year observational study.
Delpeuch A; Ruivard M; Abergel A; Aumaitre O; Boisgard S; Bagel S; Sautou V
Int J Clin Pharm; 2018 Jun; 40(3):686-692. PubMed ID: 29520555
[TBL] [Abstract][Full Text] [Related]
14. Effects of a multifaceted intervention to promote the use of intravenous iron sucrose complex instead of ferric carboxymaltose in patients admitted for more than 24 h.
Touchard J; Perrin G; Berdot S; Pouchot J; Loustalot MC; Sabatier B
Eur J Clin Pharmacol; 2021 Feb; 77(2):189-195. PubMed ID: 32926203
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden.
Hofmarcher T; Borg S
J Med Econ; 2015; 18(7):492-501. PubMed ID: 25766863
[TBL] [Abstract][Full Text] [Related]
16. An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic.
Wilson PD; Hutchings A; Jeans A; Macdougall IC
J Med Econ; 2013; 16(1):108-14. PubMed ID: 22989163
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of erythropoiesis-stimulating agents for anemia related to cancer.
Klarenbach S; Manns B; Reiman T; Reaume MN; Lee H; Lloyd A; Wiebe N; Hemmelgarn B; Tonelli M
Cancer; 2010 Jul; 116(13):3224-32. PubMed ID: 20564645
[TBL] [Abstract][Full Text] [Related]
18. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
19. Budget impact of parenteral iron treatment of iron deficiency: methodological issues raised by using real-life data.
Brock E; Braunhofer P; Troxler J; Schneider H
Eur J Health Econ; 2014 Dec; 15(9):907-16. PubMed ID: 24081613
[TBL] [Abstract][Full Text] [Related]
20. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose.
Christoph P; Schuller C; Studer H; Irion O; De Tejada BM; Surbek D
J Perinat Med; 2012 May; 40(5):469-74. PubMed ID: 22945271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
